The securities of Imagion Biosystems Limited (‘IBX’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX
Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has achieved a key
Appendix 4D, Half-year report of 30th June, 2019, has been lodged with the Australian Securities Exchange. View Appendix 4D Half-year report.
Appendix 3X (Initial Director’s Interest Notice) in relation to the appointment of Dr. Hazle effective July 30th, 2018. View and download Appointment of Director and
Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 30 June 2018 is posted. View and download Appendix 4C
“Form 604 notice of changes of interests of substantial holder” is posted. View and download Form 604 notice of changes of interests of substantial holder.
“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” of 19 June, 2018 is posted. View and download Appendix 3B New
“Appendix 3Y Change of Director’s Interest Notice” is posted. View and download “Appendix 3Y Change of Director’s Interest Notice“.
“Notice Pursuant to Section 708A(5)(e) of the Corporations Act” is posted. View and download Notice Pursuant to Section 708A(5)(e) of the Corporations Act.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance